VRB-101 EVOLVE-2 topline
EVOLVE-2 tests weekly oral ecnoglutide in obesity/overweight, using mean percentage body-weight change after twenty weeks. Verdiva completed enrollment and targeted topline by year-end 2026.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Current private investment classification is explicitly supported by investor RA Capital; recheck before activation.
- This study is distinct from any separate GLP-1 switching study; registry completion and public results disclosure are different events.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Company target: by end of 2026; exact day unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will Verdiva publicly report EVOLVE-2’s prespecified primary analysis by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.